Recruiting
Investigational
A study to assess the safety of anumigilimab in adults with sickle cell disease
Investigational
- Substances:Anumigilimab
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Anumigilimab
Find therapies in clinical trials near you – page 23
- recruiting
- 3 982
- countries
- 28
- conditions
- 2 106
3 982 trials recruiting28 European countries2 106 conditions coveredUpdated today
3 662 trials match your criteria
Recruiting
Pulmonary arterial hypertension
RecruitingA study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.
Investigational
A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.
Investigational
- Disease:Pulmonary arterial hypertension
- Substances:–
Countries:Italy
Italy- Participants:18–64 years · 65+ years
Recruiting
Type 2 diabetes mellitus+1
RecruitingA study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity
Investigational
A study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity
Investigational
- Disease:Type 2 diabetes mellitusObesity
- Substances:CagrilintideSemaglutide
Countries:Italy
Italy- Participants:0–17 years
- Substances:Cagrilintide
Recruiting
Ovarian cancer
RecruitingA study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy
Registered drugNo placebo
A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy
Registered drugNo placebo
- Disease:Ovarian cancer
- Substances:BevacizumabSacituzumab Tirumotecan
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
Recruiting
Ductal adenocarcinoma of pancreas
RecruitingA study of daraxonrasib (RMC-6236) compared to observation in patients with resected pancreatic cancer following chemotherapy
InvestigationalNo placebo
A study of daraxonrasib (RMC-6236) compared to observation in patients with resected pancreatic cancer following chemotherapy
InvestigationalNo placebo
- Disease:Ductal adenocarcinoma of pancreas
- Substances:(12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:(12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
Recruiting
Colitis ulcerative+1
RecruitingA study of mirikizumab levels in breast milk of breastfeeding women with ulcerative colitis or Crohn's disease
Registered drugNo placebo
A study of mirikizumab levels in breast milk of breastfeeding women with ulcerative colitis or Crohn's disease
Registered drugNo placebo
- Disease:Colitis ulcerativeCrohn's disease
- Substances:Mirikizumab
Countries:Italy
Italy- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Mirikizumab
Recruiting
Chronic lymphocytic leukaemia recurrent+1
RecruitingA study of acalabrutinib and venetoclax for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have relapsed after initial treatment
Registered drugNo placebo
A study of acalabrutinib and venetoclax for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have relapsed after initial treatment
Registered drugNo placebo
- Disease:Chronic lymphocytic leukaemia recurrentB-cell small lymphocytic lymphoma recurrent
- Substances:AcalabrutinibVenetoclax
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Acalabrutinib
Recruiting
Homocystinuria
RecruitingA study to evaluate the safety and effectiveness of pegtibatinase in patients aged 12 to 65 years with classical homocystinuria.
Investigational
A study to evaluate the safety and effectiveness of pegtibatinase in patients aged 12 to 65 years with classical homocystinuria.
Investigational
- Disease:Homocystinuria
- Substances:–
Countries:Italy
Italy- Participants:0–17 years · 18–64 years · 65+ years
Recruiting
Neoplasm malignant
RecruitingA study of PM54 and pembrolizumab in adults with advanced cancer
Registered drugNo placebo
A study of PM54 and pembrolizumab in adults with advanced cancer
Registered drugNo placebo
- Disease:Neoplasm malignant
- Substances:Pembrolizumab
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
Recruiting
Hepatocellular carcinoma
RecruitingA study of pumitamig and ipilimumab in patients with advanced or unresectable liver cancer
Registered drugNo placebo
A study of pumitamig and ipilimumab in patients with advanced or unresectable liver cancer
Registered drugNo placebo
- Disease:Hepatocellular carcinoma
- Substances:Ipilimumab
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Ipilimumab
Recruiting
Progressive supranuclear palsy
RecruitingA study to evaluate the safety and effectiveness of NIO752 in patients with progressive supranuclear palsy
Registered drug
A study to evaluate the safety and effectiveness of NIO752 in patients with progressive supranuclear palsy
Registered drug
- Disease:Progressive supranuclear palsy
- Substances:Sodium Chloride
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Sodium Chloride
Recruiting
Neoplasm malignant
RecruitingA study of S-241656 and a drug combination in patients with certain types of cancer involving KRAS, BRAF, or other RAS/MAPK mutations
Registered drugNo placebo
A study of S-241656 and a drug combination in patients with certain types of cancer involving KRAS, BRAF, or other RAS/MAPK mutations
Registered drugNo placebo
- Disease:Neoplasm malignant
- Substances:CetuximabFluorouracil+7
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Cetuximab